vs
Antero Midstream Corp(AM)とPacira BioSciences, Inc.(PCRX)の財務データ比較。上の社名をクリックして会社を切り替えられます
Antero Midstream Corpの直近四半期売上が大きい($297.0M vs $196.9M、Pacira BioSciences, Inc.の約1.5倍)。Pacira BioSciences, Inc.の前年同期比売上増加率が高い(5.1% vs 3.3%)。過去8四半期でPacira BioSciences, Inc.の売上複合成長率が高い(8.5% vs 3.2%)
Antero Midstream Corpは米国のエネルギー企業で、デラウェア州に法人登録され、本社をコロラド州デンバーに置く。同社の石油・天然ガス埋蔵量は全てアパラチア盆地にあり、水圧破砕技術を用いて採掘を行っている。
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
AM vs PCRX — 直接比較
売上が大きい
AM
1.5倍大きい
$196.9M
売上成長率が高い
PCRX
+1.8%の差
3.3%
2年売上CAGRが高い
PCRX
2年複合成長率
3.2%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $297.0M | $196.9M |
| 純利益 | $51.9M | — |
| 粗利率 | — | 79.5% |
| 営業利益率 | 33.8% | 1.2% |
| 純利益率 | 17.5% | — |
| 売上前年比 | 3.3% | 5.1% |
| 純利益前年比 | -53.3% | — |
| EPS(希薄化後) | $0.11 | $0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上
AM
PCRX
| Q4 25 | $297.0M | $196.9M | ||
| Q3 25 | $294.8M | $179.5M | ||
| Q2 25 | $305.5M | $181.1M | ||
| Q1 25 | $291.1M | $168.9M | ||
| Q4 24 | $287.5M | $187.3M | ||
| Q3 24 | $269.9M | $168.6M | ||
| Q2 24 | $269.8M | $178.0M | ||
| Q1 24 | $279.1M | $167.1M |
純利益
AM
PCRX
| Q4 25 | $51.9M | — | ||
| Q3 25 | $116.0M | $5.4M | ||
| Q2 25 | $124.5M | $-4.8M | ||
| Q1 25 | $120.7M | $4.8M | ||
| Q4 24 | $111.2M | — | ||
| Q3 24 | $99.7M | $-143.5M | ||
| Q2 24 | $86.0M | $18.9M | ||
| Q1 24 | $103.9M | $9.0M |
粗利率
AM
PCRX
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% | ||
| Q1 24 | — | 71.6% |
営業利益率
AM
PCRX
| Q4 25 | 33.8% | 1.2% | ||
| Q3 25 | 61.2% | 3.5% | ||
| Q2 25 | 61.0% | 4.7% | ||
| Q1 25 | 60.9% | 1.2% | ||
| Q4 24 | 61.8% | 13.2% | ||
| Q3 24 | 60.2% | -82.8% | ||
| Q2 24 | 56.6% | 15.9% | ||
| Q1 24 | 59.6% | 7.9% |
純利益率
AM
PCRX
| Q4 25 | 17.5% | — | ||
| Q3 25 | 39.3% | 3.0% | ||
| Q2 25 | 40.8% | -2.7% | ||
| Q1 25 | 41.5% | 2.8% | ||
| Q4 24 | 38.7% | — | ||
| Q3 24 | 37.0% | -85.1% | ||
| Q2 24 | 31.9% | 10.6% | ||
| Q1 24 | 37.2% | 5.4% |
EPS(希薄化後)
AM
PCRX
| Q4 25 | $0.11 | $0.05 | ||
| Q3 25 | $0.24 | $0.12 | ||
| Q2 25 | $0.26 | $-0.11 | ||
| Q1 25 | $0.25 | $0.10 | ||
| Q4 24 | $0.23 | $0.38 | ||
| Q3 24 | $0.21 | $-3.11 | ||
| Q2 24 | $0.18 | $0.39 | ||
| Q1 24 | $0.21 | $0.19 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $180.4M | $238.4M |
| 総負債低いほど良い | $3.2B | $372.2M |
| 株主資本純資産 | $2.0B | $693.1M |
| 総資産 | $5.9B | $1.3B |
| 負債/資本比率低いほどレバレッジが低い | 1.63× | 0.54× |
8四半期トレンド — 暦四半期で整列
現金・短期投資
AM
PCRX
| Q4 25 | $180.4M | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M | ||
| Q1 24 | $26.1M | $325.9M |
総負債
AM
PCRX
| Q4 25 | $3.2B | $372.2M | ||
| Q3 25 | $3.0B | $376.7M | ||
| Q2 25 | $3.0B | $580.5M | ||
| Q1 25 | $3.1B | $583.4M | ||
| Q4 24 | $3.1B | $585.3M | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | — | ||
| Q1 24 | $3.2B | — |
株主資本
AM
PCRX
| Q4 25 | $2.0B | $693.1M | ||
| Q3 25 | $2.1B | $727.2M | ||
| Q2 25 | $2.1B | $757.8M | ||
| Q1 25 | $2.1B | $798.5M | ||
| Q4 24 | $2.1B | $778.3M | ||
| Q3 24 | $2.1B | $749.6M | ||
| Q2 24 | $2.1B | $879.3M | ||
| Q1 24 | $2.2B | $892.2M |
総資産
AM
PCRX
| Q4 25 | $5.9B | $1.3B | ||
| Q3 25 | $5.7B | $1.3B | ||
| Q2 25 | $5.7B | $1.5B | ||
| Q1 25 | $5.8B | $1.6B | ||
| Q4 24 | $5.8B | $1.6B | ||
| Q3 24 | $5.8B | $1.5B | ||
| Q2 24 | $5.8B | $1.6B | ||
| Q1 24 | $5.7B | $1.6B |
負債/資本比率
AM
PCRX
| Q4 25 | 1.63× | 0.54× | ||
| Q3 25 | 1.46× | 0.52× | ||
| Q2 25 | 1.45× | 0.77× | ||
| Q1 25 | 1.49× | 0.73× | ||
| Q4 24 | 1.47× | 0.75× | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.50× | — | ||
| Q1 24 | 1.48× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $255.5M | $43.7M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $43.5M |
| FCFマージンFCF / 売上 | — | 22.1% |
| 設備投資強度設備投資 / 売上 | — | 0.1% |
| キャッシュ転換率営業CF / 純利益 | 4.92× | — |
| 直近12ヶ月FCF直近4四半期 | — | $136.7M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフロー
AM
PCRX
| Q4 25 | $255.5M | $43.7M | ||
| Q3 25 | $212.8M | $60.8M | ||
| Q2 25 | $265.2M | $12.0M | ||
| Q1 25 | $198.9M | $35.5M | ||
| Q4 24 | $232.7M | $33.1M | ||
| Q3 24 | $184.9M | $53.9M | ||
| Q2 24 | $215.8M | $53.2M | ||
| Q1 24 | $210.6M | $49.1M |
フリーキャッシュフロー
AM
PCRX
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | $184.3M | $49.8M | ||
| Q2 24 | $147.2M | $51.6M | ||
| Q1 24 | $208.5M | $46.3M |
FCFマージン
AM
PCRX
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | 68.3% | 29.6% | ||
| Q2 24 | 54.6% | 29.0% | ||
| Q1 24 | 74.7% | 27.7% |
設備投資強度
AM
PCRX
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.2% | 2.4% | ||
| Q2 24 | 25.4% | 0.9% | ||
| Q1 24 | 0.7% | 1.7% |
キャッシュ転換率
AM
PCRX
| Q4 25 | 4.92× | — | ||
| Q3 25 | 1.84× | 11.20× | ||
| Q2 25 | 2.13× | — | ||
| Q1 25 | 1.65× | 7.37× | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 2.51× | 2.82× | ||
| Q1 24 | 2.03× | 5.47× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AM
| Gathering Low Pressure | $114.2M | 38% |
| Natural Gas Water Handling And Treatment Affiliate | $63.2M | 21% |
| Water Handling | $55.7M | 19% |
| Fresh Water Delivery | $37.2M | 13% |
| Other Fluid Handling | $26.9M | 9% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |